The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. Market Capitalization ...

Officers at Los Angeles International Airport uncovered more than 17 pounds of liquid methamphetamine concealed in plastic bottles labeled as dog shampoo this month. Officials said the estimated ...

Advance Personal Care Limited (APCL), a concern of Pran Group, has stepped into the booming pet care industry by launching its first-ever pet shampoo: Adora Aloe-Oatbath. "The number of pet lovers ...

Like DB, Ocular Rosacea is a large and underserved market that affects approximately 15 million to 18 million Americans, with the majority of cases caused by an infestation of Demodex mites.

Presented new data showing the global prevalence and real-world patient burden of Demodex blepharitis (DB ... agent that paralyzes and kills mites by selectively inhibiting parasite-specific ...

Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as ...

Presented new data showing the global prevalence and real-world patient burden of Demodex blepharitis (DB ... a well-characterized anti-parasitic agent that paralyzes and kills mites by selectively ...

Presented new data showing the global prevalence and real-world patient burden of Demodex blepharitis (DB). The Elara study showed the high prevalence and significant impact of DB in Japan ...

Tarsus Pharmaceuticals reported strong financial results in Q1 2025, driven by a significant increase in the sales of its flagship product, Xtendi. The company achieved net product sales of $78.3 ...

mites by selectively inhibiting parasite-specific ... 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential ...